Attention retirees,
If you’re willing to be at your computer between 9 am and 10:45 am on most weekdays…
I can show you one simple trade that can potentially bankroll your retirement.
Hi… I’m Dave Aquino and I help everyday Americans go after their retirement goals sooner… by teaching them how to master the retirement trade.
The Retirement Trade is designed to be used every morning between 9am and 10:45am eastern time.
Why this window?
Well… I can’t share that information here…
But don’t worry because you’ll discover the exact reason why inside the free report you see pictured below…
And it’s yours - for FREE!
But please don’t delay, because it might not be free for long.
Just click here to claim it today...
Dave Aquino
Partner, Head of Options Trading
Base Camp Trading
Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Written by Chris Markoch. Published 10/27/2025.
Key Points
- Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks trade at stretched valuations, which can make it hard for investors to find names with the potential to double. Penny stocks (those trading below $5) are often cited as high-upside candidates, but their risk-reward profile typically suits only risk-tolerant, nimble traders.
Still, opportunities exist. One useful screen is analyst sentiment. Analysts don't always get it right, but they often have access to data and company insight that retail investors lack. Their views are therefore worth considering as part of due diligence.
Trump's Law S.1582: $21T Dollar Revolution Coming (Ad)
Do you have money in any of these banks?
Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp.
If you do…
With that in mind, here are three stocks currently trading for less than $50 per share that analysts see as having significant upside. While analysts aren't necessarily predicting a doubling for each, the consensus price targets are close enough that a favorable economic backdrop could push them much higher.
Equinox Gold: Gold's Momentum Could Keep Running
Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold miner. As of Oct. 27, EQX stock is up roughly 100% year to date, yet analysts assign a consensus price target of $26, implying upside of more than 149% from current levels.
Equinox is essentially a leveraged play on the rally in gold prices. Many analysts view mining stocks such as EQX as an efficient way for equity investors to capture gains from rising bullion prices. The most bullish forecasts envision the spot price of gold reaching $5,000 before the end of 2025, with further gains possible in 2026.
Higher spot prices boost Equinox's mining economics, while the primary risk is a reversal in the gold trade. Institutional ownership of EQX is about 38%, but it has been climbing sharply over the past 12 months and has risen steadily for more than two years—an encouraging sign of growing institutional interest.
Birkenstock: A Consumer Stock Ready to Rebound
Consumer discretionary names have had a rough 2025, and Birkenstock Group AG (NYSE: BIRK) is no exception. BIRK is down about 25% so far this year, but that decline may reflect a broad sector pullback rather than company-specific weakness.
Birkenstock is showing solid fundamentals: year-over-year revenue and earnings are higher, with double-digit revenue growth across segments and channels. Analysts expect earnings to grow more than 26% over the next 12 months, which sits alongside a forward price-to-earnings (P/E) ratio near 23x.
Another potentially attractive factor is elevated short interest—around 17%—which has eased slightly in the past month. That could indicate short sellers are losing conviction and still leaves room for a short squeeze if the stock rallies sharply.
Analysts give BIRK a consensus price target of $68.38, implying roughly 58% upside. The company reports third-quarter results on Dec. 17, and a strong holiday season could help push the stock higher into 2026.
Immunocore: Biotech With Breakthrough Potential
Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer treatments using T-cell technology. As of August 2025, the company has one drug that has successfully completed clinical trials and three candidates in or about to enter Phase 3.
Biotech stocks are often labeled as double-or-nothing investments because a single regulatory or commercial success can dramatically boost a company's valuation. Immunocore is beginning to generate meaningful revenue and may be on a path toward profitability.
Analysts assign IMCR a consensus price target of $61. More bullishly, HC Wainwright reiterated a Buy rating on Oct. 22 and set a $100 target. Not all analysts share that optimism—Weiss analysts, for example, rate the stock a Sell, arguing much of the expected growth is already priced in.
This email communication is a sponsored message sent on behalf of Base Camp Trading, a third-party advertiser of DividendStocks.com and MarketBeat.
This promotional message is sent on behalf of Base Camp Trading, located at 5540 Centerview Drive, Suite 204, Raleigh, NC 27606. If you no longer wish to receive promotional emails from Base Camp Trading, please unsubscribe here with the "optout" in the subject line.
If you have questions about your newsletter, don't hesitate to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl. #620, Sioux Falls, South Dakota 57103. United States of America..